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Objective: We evaluated the effect of pretreatment with nitric oxide precur-
sor before ischemia on recovery with reperfusion in rat hearts. Methods:
Isolated rat hearts were perfused with Krebs-Henseleit buffer without (C
group) or with 3 mmol/L L-arginine (A group) before 30 minutes of
ischemia. The left ventricular function, including heart rate, developed
pressure, maximal dp/dt, and coronary flow, were measured before pre-
treatment and after 10 and 30 minutes of reperfusion. Cyclic guanosine
monophosphate (by radioimmunoassay), calcium (by absorption spectro-
photometry), and inositol 1,4,5-triphosphate synthesized from tritiated
myo-inositol (by ion-exchange chromatography preceding counting) were
measured at the same times and immediately after ischemia. Results:
Recovery of ventricular function was significantly greater in the A group
than in the C group. Pretreatment increased postischemic cyclic guanosine
monophosphate content compared with the preischemic level (from 1.06 6
0.12 to 1.94 6 0.09 pmol/mg protein, p < 0.05). No change in cyclic
guanosine monophosphate was evident in the C group. In the C group,
inositol triphosphate content increased after 10 minutes of reperfusion
beyond the preischemic level (from 0.53 6 0.023 to 1.15 6 0.045 cpm 3
10-3/gm, p < 0.05) as did calcium at 30 minutes (from 4.12 6 0.164 to 6.86 6
0.544 mmol/gm dry weight). In the A group, both of these increases were
significantly attenuated. Conclusion: These data suggest that L-arginine
pretreatment may reduce calcium overload by increasing cyclic guanosine
monophosphate production, which in turn downregulates inositol triphos-
phate synthesis during reperfusion. (J Thorac Cardiovasc Surg 1998;115:
931-6)
Nitric oxide (NO), an endothelially derived,smooth muscle–relaxing factor, is well known as
a physiologically important vasodilator. Recent pa-
pers have suggested that NO also is a regulator of
cell metabolism, which can reduce adenosine
triphosphate (ATP) by inhibiting glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and mito-
chondrial function1 and cause cell injury by produc-
tion of peroxynitrite.2, 3
Previous studies have demonstrated that NO in-
creases cyclic guanosine monophosphate (cGMP) in
vascular smooth muscle cells by activation of soluble
guanylate cyclase (sGC).4 Other investigators have
reported that cGMP decreases the cytosolic Ca21
content, or [Ca21]i through several mechanisms,
including inhibition of the phosphatidylinositol
pathway,5, 6 indirect inhibition of Ca21 channels,7
and stimulation of plasma membrane Ca21
pumps.8, 9
In addition, some studies have linked the cardio-
protective effects of NO in ischemia-reperfused
hearts to attenuation of neutrophil accumulation
and adhesion,10-16 inhibition of superoxide anion
production,17-19 and protection of coronary endo-
thelial cell function.11, 20 An NO precursor as a
pretreatment or an addition to a cardioplegic solu-
tion is an appealing prospect in cardiac surgery,
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provided it is safe. We explored mechanisms of
cardioprotection by such pretreatment in isolated
rat hearts.
Methods
The investigation was performed in accordance with the
guidelines in the Guide for the Care and Use of Labora-
tory Animals published by the U.S. National Institutes of
Health (NIH publication No 85-23, revised 1985).
Experimental preparation. Male Sprague-Dawley rats
(body weight 250 to 300 gm) were anesthetized by intra-
peritoneal injection of pentobarbital (80 mg/kg) and hep-
arinized (200 units via the femoral vein). After thoracot-
omy, their hearts were rapidly excised and arrested in
cold-modified Krebs-Henseleit bicarbonate buffer solu-
tion (mKHB buffer: NaCl, 118 mEq/L; KCl, 4.7 mEq/L;
KHPO4, 1.2 mEq/L; NaHCO3, 24 mEq/L; MgSO4, 1.2
mEq/L; glucose, 10 mEq/L; CaCl2, 1.7 mEq/L; gassed with
95% oxygen and 5% carbon dioxide, pH 7.4). The ascend-
ing aorta was cannulated and hearts were perfused in the
nonrecirculating Langendorff mode with mKHB buffer at
37° C at a pressure of 100 cm H2O for 10 minutes.
Myocardial temperature was maintained at 37° C by a
surrounding water jacket.
Experimental protocol. The experimental protocol is
represented as a time line in Fig. 1. After an initial
10-minute perfusion, hearts were perfused another 10
minutes with mKHB buffer (C group) or with mKHB
buffer containing 3 mmol/L L-arginine (A group, Sigma
Chemical Co., St. Louis, Mo.). The hearts were then
subjected to 30 minutes of normothermic global ischemia,
after which they were perfused with mKHB buffer at 37° C
for 30 minutes. Modified KHB buffer was gassed with 95%
oxygen and 5% carbon dioxide during the experiments,
and oxygen tension of mKHB was kept higher than 600
mm Hg after reperfusion. Contractile functions were
obtained at baseline before the first perfusion (Base) and
after 10 (R10) and 30 minutes (R30) of reperfusion.
Tissue samples for the measurement of cGMP, inositol
phosphates, and calcium content were obtained each time
from the separate rats, which were perfused and reper-
fused on the same protocol. Rats were randomly assigned
to the treatment group and the resected tissue samples of
each time. Total number of the hearts was 96.
Myocardial contractile function. Aspects of left ven-
tricular function evaluated included heart rate (beats/
min), maximum developed pressure (dp max, mm Hg),
the first derivative of the left ventricular pressure (LV
dp/dt max, mm Hg/sec), and coronary blood flow. Pres-
sures were measured with a fluid-filled compliant balloon
(0.5 ml) that was connected by fluid-filled polyethylene
tubing to a pressure transducer (P23ID; Gould, Inc.,
Cleveland, Ohio). The balloon was inserted into the left
ventricle through the mitral valve. Developed pressure
was measured as the difference between peak systolic
pressure and end-diastolic pressure. Coronary flow (ml/
min) was assessed by measuring the volume of coronary
effluent ones (n 5 12; six rats were used in each group.
These 12 hearts were also used as the samples of intra-
cellular Ca21 concentration and cGMP after 30 minutes
of reperfusion.)
Intracellular calcium concentration. After left ventric-
ular function was measured and also after ischemia,
transmural tissue specimens were obtained from the left
ventricular wall. Myocardial calcium (Ca) concentrations
were determined using atomic absorption spectrophotom-
etry. Approximately 0.3 gm of myocardial tissue was
homogenized with lanthanum chloride and hydrochloride
solution to avoid interference by protein or anions. The
supernatant obtained from homogenates centrifuged for
15 minutes at 10,000 rpm was used for measurement of
Ca21 with the 422.7 nm line of a Ca hollow-cathode lamp
Fig. 1. Experimental protocol: A time line is given for the study as conducted in each heart. After 5
minutes of Langendorff perfusion (L-P) with normal modified Krebs-Henseleit bicarbonate buffer (KHB),
baseline myocardial functions were carried out. After this, L-P with drugs buffered in KHB was established
for a total of 10 minutes and then the heart was replaced for 30 minutes of normothermic global ischemia
and reperfused with normal KHB for 30 minutes. Biopsy specimens for cGMP and calcium were taken at
the baseline point, 30 minutes after ischemia, 10 minutes after reperfusion, and 30 minutes after
reperfusion. In addition, separate hearts were perfused for 45 minutes with 50 ml KHB containing 20 mCi
of [3H] myo-inositol for the measurements of inositol-1,4,5-monophosphate. In the C group no drug was
used, whereas the L group had L-arginine administered for 10 minutes before ischemia.
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(n 5 48; six rat hearts were used at each time of each
group. All hearts were also used at the measurement of
cGMP)
Measurement of cGMP. Cyclic GMP was measured in
the heart by a radioimmunoassay. Tissue samples were
taken at the same times as for Ca measurements and
immediately frozen in liquid nitrogen. The samples were
homogenized in 0.1 ml of a 0.1 N HCl–10 mmol/L
ethylenediaminetetraacetic acid solution and then im-
mersed in boiling water for 3 minutes to provide an acid
extract suitable for measurements of cGMP concentra-
tion. One hundred microliters of sample (either a cGMP
standard or a test solution) was added to 100 mL of a
dioxane-triethylamine mixture containing succinic anhy-
dride. After 10 minutes at room temperature, the reaction
mixture was added to 0.5 to 1.0 ml of 0.5 mmol/L
imidazole buffer containing 0.5% bovine serum albumin,
8 mmol/L theophylline, and 0.001% streptomycin. The
above mixture (100 ml) was added to 100 ml of
[125I]SCAMPTME (15,000 to 20,000 cpm in an amount
less than 104 mol) and 100 ml of the diluted antisera. The
mixture was kept at 4° C overnight (about 15 hours). A
cold solution of dextran-coated charcoal (0.5 ml) was
added to the above mixture and cooled in an ice-cold
water bath. The charcoal was then spun down, and 0.5 ml
of the supernatant was counted for radioactivity in a
gamma spectrometer (n 5 48).
Measurement of phosphatidylinositols. Separate
hearts were processed to measure inositol-1,4,5-mono-
phosphate content. After stabilization, they were perfused
for 45 minutes with 50 ml mKHB buffer containing 20 mCi
of [3H] myo-inositol, and then perfused with mKHB
buffer containing 10 mmol/L LiCl to inhibit inositol
phosphate phosphatase. They then were randomly as-
signed either the C group or A group. At the same times
as for calcium measurements, the left ventricle was ex-
cised from the heart and rapidly frozen in liquid nitrogen.
For measurement of [3H] inositol triphosphate, the frozen
tissue was homogenized with 5% perchloric acid with a
Polytron homogenizer (Brinkmann Instruments, Inc.,
Westbury, N.Y.) and centrifuged at 8000 for 10 minutes.
The supernatant was neutralized with 5 mmol/L K2CO3,
and the precipitate was removed by centrifugation at
1000g for 5 minutes. The supernatant was applied to the
anion exchange column. The 1 ml fractions eluted from
the column were counted in duplicate for radioactivity21
(n 5 48; six hearts were used at each time in each group).
Statistical analysis. Results are expressed as mean 6
standard error of the mean for the number of observa-
tions. Data were analyzed by analysis of variance
(ANOVA)-factorial for differences between the groups
using Scheffe’s test, and by ANOVA-repeated measure-
ments for accounting for potential changes between the
different points of time throughout the experimental
protocol within the group by using Scheffe’s test.
ANOVA-repeated measurements were applied to each
parameter for examining both entire measuring points
(data from the preischemic baseline to the end of reper-
fusion) and points after reperfusion. Sequential changes
in each parameter also were examined by paired t test in
each group. A level of p , 0.05 was accepted as being
statistically significant.
Results
Hemodynamics. No episodes of ventricular ar-
rhythmia occurred after reperfusion in either group.
Left ventricular functional data for the two groups
at baseline before entering the group protocols and
after 10 or 30 minutes of reperfusion are displayed
in Table I.
In the group pretreated with L-arginine, dp max
and LV dp/dt max were significantly higher than in
the control group after 10 and 30 minutes of reper-
fusion. No significant differences in heart rate were
noted between the L-arginine–pretreated group and
the control group.
In the C group but not the A group, coronary flow
was significantly reduced at 30 minutes of reperfu-
sion compared with the preischemic values.
Tissue cGMP content (Fig. 2). After 30 minutes
of ischemia and reperfusion, cGMP content was
significantly increased in the L-arginine–pretreated
group (base: 1.06 6 0.12, I30: 1.94 6 0.09, R10:
1.88 6 0.14, R30: 1.55 6 0.10 pmol/mg protein),
compared with the C group (base: 1.04 6 0.14, I30:
Table I. Cardiac function
Variable Baseline R10 R30
Developed pressure (mm Hg) C group 102.5 6 9.5 47.7 6 12.3* 57.3 6 12.2*
A group 103.0 6 8.2 98.3 6 11.5*† 94.8 6 5.3*†
LVdp/dt max (mm Hg/sec) C group 1039 6 131 418 6 108* 490 6 122*
A group 1101 6 119 822 6 69† 875 6 48†
Coronary flow (ml/min) C group 15.9 6 1.0 11.4 6 2.5* 9.0 6 1.9*
A group 16.7 6 0.9 17.1 6 0.9† 14.3 6 1.3†
Heart rate (beats/min) C group 195.0 6 23.0 118.8 6 32.7* 122.7 6 28.0*
A group 216.0 6 23.2 193.0 6 32.5 174.7 6 16.9
R 10, 10 minutes reperfusion; R 30, 30 minutes reperfusion.
*p , 0.05, compared with baseline value.
†p , 0.05, C group versus A group.
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1.26 6 0.08, R10: 1.25 6 0.14, R30: 1.00 6 0.09
pmol/mg protein, p 5 0.02) at each time except for
base. No change in cGMP content was evident in the
control group during the experiment.
Inositol 1,4,5-triphosphate (IP3; Fig. 3). In the
control group, IP3 was significantly increased after
10 and 30 minutes of reperfusion compared with
baseline and after 30 minutes of ischemia (base:
0.59 6 0.045, I30; 0.53 6 0.023, R10: 1.15 6 0.045,
R30: 0.98 6 0.056 cpm 3 1023/gm, p 5 0.01).
However, in the L-arginine–pretreated group, no
differences were found between preischemic values
and those after 30 minutes of ischemia, 10 minutes
of reperfusion, and 30 minutes of reperfusion (base:
0.52 6 0.042, I30; 0.51 6 0.054, R10: 0.61 6 0.062,
R30: 0.68 6 0.032 cpm x1023/gm, p 5 0.02), and the
values of R10 and R30 in the A group were signif-
icantly lower than those in the C group, respectively
(p 5 0.03).
Ca21 content (Fig. 4). In both groups, Ca21
content was significantly increased after 30 minutes
of ischemia compared with preischemic values, with
no differences between two groups.
After reperfusion, however, Ca21 content signifi-
cantly increased in the control group (base: 1.46 6
0.109, I30; 4.12 6 0.164, R10: 5.11 6 0.314, R30:
6.86 6 0.544 mmol/gm dry weight, p 5 0.02). In the
L-arginine–pretreated group, no significant change
in Ca21 was noted after reperfusion (base: 1.46 6
0.109, I30: 3.72 6 0.214, R10: 3.68 6 0.158, R30:
3.14 6 0.428 mmol/gm dry weight, p 5 0.01).
Discussion
Previous studies have suggested that NO protects
against ischemia-reperfusion injury, and cardiopro-
tective mechanisms may be due to coronary vasodi-
latation, inhibition of neutrophil adherence, inhibi-
tion of platelet aggregation, protection of coronary
endothelial cell function, and neutralization of free
radicals. Other studies, reporting detrimental effects
of NO on hearts in reperfusion2, 3, 22 have suggested
that NO inhibits mitochondrial function and pro-
duces peroxynitrite. Taken together, these results
Fig. 2. Cyclic GMP content. cyclic GMP (cGMP) con-
tents in the myocardium were measured by radioimmu-
noassay at baseline (Base), after 30 minutes of ischemia
(I30), after 10 minutes reperfusion (R10), and after 30
minutes reperfusion (R30). In the L group, cGMP con-
tents were significantly higher than the C group after
ischemia and reperfusion. *p 5 0.02, C group versus L
group; #p 5 0.01 compared with the values of baseline.
Fig. 3. The content of inositol-1,4,5-monophosphate
(IP3). IP3 significantly increased 10 minutes and 30 min-
utes after reperfusion in the C group. However, in the L
group there was no differences between the value of
baseline and after reperfusion. *p 5 0.03, C group versus
L group; #p 5 0.01, compared with the values of baseline.
Fig. 4. Cytosolic Ca21 content. Cytosolic Ca21 content
significantly increased after ischemia and reperfusion in
both groups. However, in the C group, the absolute values
were significantly higher in the L group after reperfusion.
*p 5 0.01, C group versus L group; #p 5 0.02, compared
with the values of baseline.
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suggest that NO has opposing effects, both benefi-
cial and detrimental, on myocardium and coronary
endothelium in this situation.
Because NO has the detrimental effects of the
ischemia-reperfusion myocardial injury, the concen-
tration of L-arginine and the timing of L-arginine
infusion have been difficult problems. In our exper-
iment the infusion of higher than 3 mmol/L L-
arginine caused the inhibition of cardiac function
(result was not shown). Engelman and colleagues23
reported that the different timing of L-arginine
infusion led the detrimental effects of cardioprotec-
tion. They reported that preischemic infusion of
L-arginine reduced reperfusion injury, but L-arginine
infusion during reperfusion did not lead to a cardio-
protective effect. Matheis and colleagues22 reported
that administration of the NO synthase inhibitor to
the extracorporeal circuit afforded protection
against myocardial reoxygenation injury. The ex-
treme release of NO on the reperfusion or reoxy-
genation phase may stimulate some cytotoxic oxygen
radical production and promotes the reperfusion
injury.
Given the complexity of these results, we specu-
lated that NO may have different effects on the
myocardium in the ischemic phase and the reperfu-
sion phase.23 In this study we investigated how
preischemic increase of NO influences the cardio-
protection on the reperfusion phase, especially re-
garding any association between NO and Ca21
overload.
Although Ca21 is important in cell metabolism as
a second messenger, extreme accumulations in the
cytosol cause cell injury. Such accumulation in
hearts during ischemia-reperfusion is known as
Ca21 overload, which contributes to reperfusion
injury, including myocardial stunning. Ca21 over-
load is caused by failure of three regulatory systems
of cytosolic Ca21 content: the cell membrane,
through which Ca21 normally cannot pass; Ca21
pumps and channels related to the membrane; and
mechanisms sequestering intracellular Ca21 stores.
Previous investigators have found that inhibition of
Ca21 overload with various calcium channel block-
ers reduces reperfusion injury. The sarcoplasmic
reticulum also is critical to regulation of intracellu-
lar Ca21 stores24 and release of calcium from the
sarcoplasmic reticulum is mediated by IP3. In this
study we observed that IP3 increased after 10 and 30
minutes of reperfusion compared with preischemic
values, as did Ca. The relationship between IP3 and
Ca in our results suggests that increased IP3 induced
more Ca accumulation, resulting in reperfusion in-
jury.25-28
We now consider the mechanism by which NO
reduces IP3 after reperfusion. As an intracellular
messenger, NO activates sGC, which causes an
increase in cGMP concentration. The diverse bio-
logic effects of cGMP include relaxation of vascular
smooth muscle, inhibition of platelet aggregation,
and regulation of phosphodiesterase and protein
kinase. Clementi and coworkers29 reported that in
neural cells NO appeared to modulate inositol
phosphate generation and Ca21 release primarily at
the level of phospholipase C, mediated by cGMP-
dependent protein kinase I. Evans and colleagues30
have demonstrated that increasing the level of
cGMP in the myocardium inhibited both positive
inotropic and phosphatidylinositol responses to a1-
stimulation in isolated preparations of papillary
muscle. Hirata and coworkers5 investigated the
mechanism of cGMP inhibition of inositol phos-
phate formation in rat aorta, and Nakashima and
coworkers6 reported cGMP inhibition of polyphos-
phoinositide hydrolysis in human platelets. Our data
show that cGMP accumulation is significantly higher
in the L-arginine–pretreatment group than in the
control group after reperfusion, and it was thought
that accumulated cGMP in the treated group inhib-
ited the increase of IP3 and Ca21 in the similar
mechanism, followed by significantly better cardio-
protection.
Previous studies have demonstrated cardioprotec-
tive mechanisms of NO caused by coronary vasodi-
latation. However, our results demonstrate other
mechanisms. These data in our study indicate that
the cardioprotective effect of L-arginine pretreat-
ment may be due to the inhibition of calcium
overload by means of cGMP.
Because NO has various effects including per-
oxynitrite production, further preclinical studies are
necessary to refine dosage and timing of the NO
precursor pretreatment protocol.23
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